Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells.

Zwergel C, Schnekenburger M, Sarno F, Battistelli C, Manara MC, Stazi G, Mazzone R, Fioravanti R, Gros C, Ausseil F, Florean C, Nebbioso A, Strippoli R, Ushijima T, Scotlandi K, Tripodi M, Arimondo PB, Altucci L, Diederich M, Mai A, Valente S.

Clin Epigenetics. 2019 May 6;11(1):68. doi: 10.1186/s13148-019-0663-8.


Redox biology of regulated cell death in cancer: A focus on necroptosis and ferroptosis.

Florean C, Song S, Dicato M, Diederich M.

Free Radic Biol Med. 2019 Apr;134:177-189. doi: 10.1016/j.freeradbiomed.2019.01.008. Epub 2019 Jan 10. Review.


Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1'(R), 6'(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax.

Florean C, Kim KR, Schnekenburger M, Kim HJ, Moriou C, Debitus C, Dicato M, Al-Mourabit A, Han BW, Diederich M.

Mar Drugs. 2018 Dec 19;16(12). pii: E518. doi: 10.3390/md16120518.


Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells.

Florean C, Schnekenburger M, Lee JY, Kim KR, Mazumder A, Song S, Kim JM, Grandjenette C, Kim JG, Yoon AY, Dicato M, Kim KW, Christov C, Han BW, Proksch P, Diederich M.

Oncotarget. 2016 Apr 26;7(17):24027-49. doi: 10.18632/oncotarget.8210.


Novel Pharmaceutical Approaches by Natural Compound-Derived Epigenetic Regulators: Epigenetic Readers, Writers and Erasers as Therapeutic Targets.

Schnekenburger M, Florean C, Grandjenette C, Diederich M.

Curr Top Med Chem. 2016;16(7):677-9. No abstract available.


Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments.

Schnekenburger M, Florean C, Dicato M, Diederich M.

Curr Top Med Chem. 2016;16(7):745-76. Review.


When do infants understand that they can obtain a desired part of a composite object by grasping another part?

Fagard J, Florean C, Petkovic M, Rat-Fischer L, Fattori P, O'Regan JK.

Infant Behav Dev. 2015 Nov;41:169-78. doi: 10.1016/j.infbeh.2015.05.003. Epub 2015 Aug 12.


Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.

Valente S, Liu Y, Schnekenburger M, Zwergel C, Cosconati S, Gros C, Tardugno M, Labella D, Florean C, Minden S, Hashimoto H, Chang Y, Zhang X, Kirsch G, Novellino E, Arimondo PB, Miele E, Ferretti E, Gulino A, Diederich M, Cheng X, Mai A.

J Med Chem. 2014 Feb 13;57(3):701-13. doi: 10.1021/jm4012627. Epub 2014 Jan 15.


Redox regulation: natural compound as regulators of inflammation signaling.

Florean C, Diederich M.

Biochem Pharmacol. 2012 Nov 15;84(10):1223-4. doi: 10.1016/j.bcp.2012.07.001. Epub 2012 Jul 14. No abstract available.


Chromatin-modifying agents in anti-cancer therapy.

Seidel C, Florean C, Schnekenburger M, Dicato M, Diederich M.

Biochimie. 2012 Nov;94(11):2264-79. doi: 10.1016/j.biochi.2012.05.012. Epub 2012 May 22. Review.


Epigenomics of leukemia: from mechanisms to therapeutic applications.

Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M.

Epigenomics. 2011 Oct;3(5):581-609. doi: 10.2217/epi.11.73. Review.


Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis.

Clocchiatti A, Florean C, Brancolini C.

J Cell Mol Med. 2011 Sep;15(9):1833-46. doi: 10.1111/j.1582-4934.2011.01321.x. Review.


Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility.

Cernotta N, Clocchiatti A, Florean C, Brancolini C.

Mol Biol Cell. 2011 Jan 15;22(2):278-89. doi: 10.1091/mbc.E10-07-0616. Epub 2010 Nov 30.


Grp94 acts as a mediator of curcumin-induced antioxidant defence in myogenic cells.

Pizzo P, Scapin C, Vitadello M, Florean C, Gorza L.

J Cell Mol Med. 2010 Apr;14(4):970-81. doi: 10.1111/j.1582-4934.2009.00681.x.


Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.

Foti C, Florean C, Pezzutto A, Roncaglia P, Tomasella A, Gustincich S, Brancolini C.

Mol Cancer Ther. 2009 Nov;8(11):3140-50. doi: 10.1158/1535-7163.MCT-09-0431. Epub 2009 Nov 3.


Recombinant differential anchorage probes that tower over the spatial dimension of intracellular signals for high content screening and analysis.

Schembri L, Zanese M, Depierre-Plinet G, Petit M, Elkaoukabi-Chaibi A, Tauzin L, Florean C, Lartigue L, Medina C, Rey C, Belloc F, Reiffers J, Ichas F, De Giorgi F.

Anal Chem. 2009 Dec 1;81(23):9590-8. doi: 10.1021/ac9015227.


Presenilin-2 dampens intracellular Ca2+ stores by increasing Ca2+ leakage and reducing Ca2+ uptake.

Brunello L, Zampese E, Florean C, Pozzan T, Pizzo P, Fasolato C.

J Cell Mol Med. 2009 Sep;13(9B):3358-69. doi: 10.1111/j.1582-4934.2009.00755.x. Epub 2009 Mar 27.


High content analysis of gamma-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer's disease.

Florean C, Zampese E, Zanese M, Brunello L, Ichas F, De Giorgi F, Pizzo P.

Biochim Biophys Acta. 2008 Aug;1783(8):1551-60. doi: 10.1016/j.bbamcr.2008.03.012. Epub 2008 Apr 3.


Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels.

Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia G, Florean C, Bagnoli S, Binetti G, Sorbi S, Pizzo P, Fasolato C.

Cell Calcium. 2006 Jun;39(6):539-50. Epub 2006 Apr 18.


Supplemental Content

Loading ...
Support Center